Build a lasting personal brand

NOVA Medical Launches Collaborative Model to Transform Tissue Repair Commercialization

By Advos•
NOVA Medical, LLC has launched with a physician-guided, collaborative approach to bring innovative tissue repair technologies to the U.S. market, aiming to align incentives among manufacturers, surgeons, and the commercial organization while preparing for a 2027 commercial launch.
NOVA Medical Launches Collaborative Model to Transform Tissue Repair Commercialization

NOVA Medical, LLC, an emerging tissue repair and regenerative medicine company, announced its formation on November 16, 2026, unveiling a new collaborative approach to commercializing medical technologies in the U.S. healthcare market. Founded by wound care veterans and guided by plastic and tissue repair surgeons, the Texas-based company aims to differentiate itself by building its portfolio around clinical needs rather than individual products.

“Most medical technology companies begin with a product and build a commercial strategy around it,” said Dr. Christine Grogan, Co-Founder and Chief Executive Officer. “We’re taking a different approach. We believe in returning to the fundamentals of responsible wound care—putting patients first, operating with integrity and embracing innovation where it truly makes a difference.”

NOVA’s strategy spans five interconnected stages of tissue repair: Prevent, Assess, Prepare, Restore, and Close. Its Plastic Surgeon Tissue Repair Surgeon Innovation Network will help identify unmet clinical needs, evaluate emerging technologies, and guide product development. “As surgeons, we understand where clinical needs remain unmet,” said Dr. Dan Kapp, a founding member of the network. “NOVA gives us the opportunity to help shape innovation from the beginning.”

For manufacturers, NOVA offers an alternative path to commercialization by combining clinical insight, experienced commercial leadership, and shared market access—without requiring each company to build a national sales infrastructure independently. The collaborative business model is designed to align the interests of manufacturers, surgeons, and the commercial organization, with participating manufacturers potentially sharing in the portfolio’s broader financial success. “We believe the next evolution in tissue repair won’t come from any one product or company,” said Chris Bauer, Co-Founder and Chief Commercial Officer. “It will come from bringing the right technologies, clinical expertise and commercial capabilities together.”

The founding team—Grogan, Bauer, and Dawn Shepard—brings decades of experience in advanced wound care, medical devices, and commercialization, including leadership roles at KCI and other medical technology organizations. NOVA’s operating model combines NOVA Distribution, its primary commercial engine, with NOVA Consulting, which supports manufacturers entering the U.S. market. The company also intends to evaluate opportunities to develop or acquire complementary technologies.

NOVA’s broader vision is complemented by Women in Wound Care, an independently governed nonprofit focused on professional education and leadership development. More information is available at womeninwoundcare.org, while details about the company can be found at novamedical1.com.

The announcement matters because the wound care market has long been fragmented, with manufacturers often bearing the high cost of building separate sales forces. NOVA’s model could lower barriers to entry for smaller innovators and accelerate patient access to new tissue repair technologies. By giving surgeons a formal role in shaping the portfolio, the company also signals a shift toward clinician-driven commercialization—an approach that may influence how other medtech firms structure their go-to-market strategies. NOVA is advancing surgeon collaboration, manufacturer engagement, and organizational development in preparation for an anticipated 2027 commercial launch.

Advos

Advos

@advos